Pipeline 2

Overview

We are dedicated to developing a pipeline of next-generation immunotherapies for patients suffering with aggressive and/or difficult-to-treat solid tumor types. Information about our investigational products and clinical trials can be found here and clinicaltrials.gov

 

A robust clinical pipeline advancing two programs with significant potential:

  • A Regional Program (ovarian cancer) with delivery into the abdominal cavity that maximizes pharmacokinetics & tumor tissue exposure
  • A Systemic Program (solid tumors) with intravenous delivery which looks to maximize the addressable indications

Olvi-Vec

Indication

Design

Preclinical

-Phase 1

-Phase 2

-Phase 3

Anticipated Milestones

Collabor-
ators

Regional Route

Ovarian Cancer
(platinum-resistant/ refractory)
Olvi-Vec (i.pe)
+Platinum-based regimen
Topline results expected in 2H, 2025
GOG FOUNDATION logo
Cooperative Group

Systemic Route

Non-Small Cell Lung Cancer
(recurrent/platinum-ICI failure)
Olvi-Vec (IV)
+Platinum/Checkpoint inhibitor-based regimen
Expected to initiate in 1H, 2024
Small Cell Lung Cancer
(recurrent/platinum failure)
Olvi-Vec (IV)
+Platinum-based regimen
Expected interim readout in 2H, 2024

Systemic Route

Ovarian Cancer
(recurrent/platinum failure)
Olvi-Vec (IV)
+Platinum-based regimen
NEWSQARA
Greater China
Non-Small Cell Lung Cancer
(recurrent/platinum-ICI failure)
Olvi-Vec (IV)
+Platinum/Checkpoint inhibitor-based regimen

Systemic Route

Pancreatic Cancer
(recurrent)
Olvi-Vec (IV)
+Adoptive Cell Therapy
VACT logo
Worldwide Rights Ex-Greater China

Clinical Trial Phases:

Phase 1

A phase of research to describe clinical trials that focus on the safety of a drug.

Phase 2

A phase of research to describe clinical trials that gather preliminary data on whether a drug works in people who have a certain condition/disease (the drug’s effectiveness).

Phase 3

A phase of research to describe clinical trials that gather more information about a drug’s safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Expanded Access

A way for patients with serious diseases or conditions who cannot participate in a clinical trial to gain access to a medical product that has not been approved by the U.S. Food and Drug Administration (FDA).
Genelux Policy